INTELLIA THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF BIOLOGICS LICENSE APPLICATION WITH PRIORITY REVIEW FOR LONVOGURAN ZICLUMERAN (LONVO-Z) FOR HEREDITARY ANGIOEDEMA (HAE)

Reuters · 2d ago

Please log in to view news